Julie Cherrington

Julie Cherrington is an accomplished professional with extensive experience in biotechnology and pharmaceuticals. Currently serving as a Board Member for Elevation Oncology, Julie also holds the position of Chairperson of the Board for both Tolremo Therapeutics and Actym Therapeutics, Inc. Additional board memberships include Syncona Limited, Sardona Therapeutics, and MycRx. Julie's involvement with Brandon Capital Partners as a Venture Partner further showcases expertise in investment. Past roles included a Board Member position at Mirati Therapeutics until its acquisition by BMS and at KisoJi Biotechnology until March 2024. Academic qualifications include a PhD in Microbiology and Immunology from the University of Minnesota and Stanford University, along with a Master of Science and Bachelor's degree from the University of California, Davis. Julie completed postdoctoral studies at the University of California, San Francisco.